Lentinula edodes (Shiitake) – biological activity

• Authors: Bożena MUSZYŃSKA , Przemysław PAZDUR , Jan LAZUR , Katarzyna SUŁKOWSKA-ZIAJA
• Languages of publication: EN EO

Abstracts

EN

Lentinula edodes (Berk.) Pegler (shiitake) is a species with medicinal properties that is used primarily in traditional medicine, but also in conventional oncology treatment. The first records of Lentinula edodes cultivation reach back to China under the Song dynast (960-1127). The Japanese adopted the Chinese technique of shiitake cultivation, thus becoming its main producer. Currently, shiitake is used in the treatment of lifestyle diseases. Polysaccharides contained in this species strengthen the immune system, eliminate side effects of chemo and radiotherapy and have strong antitumor, antiviral and antibacterial properties. The year 1972 saw a discovery of substances with anti-atherosclerotic effects, with the most important being eritadenine (2 (R), 3 (R)-dihydroxy-4 – (9-adanyl) butyric acid) and statin – lovastatin. L. edodes is of interest to researchers due to its content of therapeutic compounds. These substances have antitumor, antifungal, antibacterial, anti-inflammatory, hypocholesterolemic, antihypertensive, hypoglycaemic and antioxidant effects.

Keywords

EN

Lentinula edodes; eritadenine; immunostimulating effect; lentinan; shiitake

Discipline

• BOTANY: BOTANY

• Journal: Medicina Internacia Revuo
• Year: 2017
• Volume: 28
• Issue: 108
• Pages: 189-195

Contributors

author

Bożena MUSZYŃSKA

• Department of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland

author

Przemysław PAZDUR

author

Jan LAZUR

author

Katarzyna SUŁKOWSKA-ZIAJA

References

• 1. Akramiene D.; Kondrotas A.; Didziapetriene J.; Kevelaitis E. Medicina (Kaunas). 2007, 43, 597-606.
• 2. Wasser, S. P. Encycl. Diet. Suppl. 2005, 653–664.
• 3. Wasser S.P.; Weis A.L. Int. J. Med. Mushr. 1999, 1, 31-62.
• 4. Casaril, K. B. P. B.; Kasuya, M. C. M.; Vanetti, M. C. D. Brazilian Arch. Biol. Technol. 2011, 54 (5), 991–1002.
• 5. Chihara, G.; Maeda, Y.; Hamuro, J.; Sasaki, T.; Fukuoka, F. Nature 1969, 222 (5194), 687–688.
• 6. Muta T. Curr. Pharm. Des. 2006, 12, 4155-4161.
• 7. Bak, W. C.; Park, J. H.; Park, Y.; Ka, K. H. Mycobiology 2014, 42 (3), 301–304.
• 8. Mizuno, T. Food Rev. Int. 1995, 11 (1), 109–128.
• 9. Kamiya, T.; Saito, Y.; Hashimoto, M.; Seki, H. Tetrahedron Lett. 1969, 10 (53), 4729–4732.
• 10. Morales, D.; Gil-Ramirez, A.; Smiderle, F. R.; Piris, A. J.; Ruiz-Rodriguez, A.; Soler-Rivas, C. Innov. Food Sci. Emerg. Technol. 2017, 41, 330-336.
• 11. Drori, A.; Shabat, Y.; Ben Ya’acov, A.; Danay, O.; Levanon, D.; Zolotarov, L.; Ilan, Y. J. Med. Food 2016, 19 (4), 383–389.
• 12. Mleczek, M.; Siwulski, M.; Rzymski, P.; Niedzielski, P.; Gąsecka, M.; Jasińska, A.; Budzyńska, S.; Budka, A. J. Environ. Sci. Heal. Part B 2017, 52 (3), 196–205.
• 13. Kurashige, S.; Akuzawa, Y.; Endo, F. Immunopharmacol. Immunotoxicol. 1997, 19 (2), 175–183.
• 14. Ogawa, T.; Ohwada, S.; Sato, Y.; Izumi, M.; Nakamura, S.; Takeyoshi, I.; Kawashima, Y.; Ohya, T.; Koyama, T.; Morishita, Y. Anticancer Res. 1998, 19 (1A), 375–379.
• 15. Murata, T.; Hatayama, I.; Kakizaki, I.; Satoh, K.; Sato, K.; Tsuchida, S. Cancer Sci. 1996, 87 (11), 1171–1178.
• 16. Kamiya, T.; Saito, Y.; Hashimoto, M.; Seki, H. J. Heterocycl. Chem. 1972, 9 (2), 359–362.
• 17. Nakano, H.; Namatame, K.; Nemoto, H.; Motohashi, H.; Nishiyama, K.; Kumada, K. Hepatogastroenterology. 1999, 46 (28), 2662–2668.
• 18. Yoshino, S.; Tabata, T.; Hazama, S.; Iizuka, N.; Yamamoto, K.; Hirayama, M.; Tangoku, A.; Oka, M. Anticancer Res. 1999, 20 (6C), 4707–4711.
• 19. Takatsuki, F.; Namiki, R.; Kikuchi, T.; Suzuki, M.; Hamuro, J. Int. J. Immunopharmacol. 1995, 17 (6), 465471–469474.
• 20. Fukushima, M.; Ohashi, T.; Fujiwara, Y.; Sonoyama, K.; Nakano, M. Exp. Biol. Med. 2001, 226 (8), 758–765.
• 21. Hirasawa, M.; Shouji, N.; Neta, T.; Fukushima, K.; Takada, K. Int. J. Antimicrob. Agents 1999, 11 (2),151–157.
• 22. Kawanobe, Y.; Sakamoto, M.; Nishioka, K. Nutr. Res. 1988, 8 (11), 1277–1286.
• 23. Takeshita, K.; Hayashi, S.; Tani, M.; Kando, F.; Saito, N.; Endo, M. Surg. Oncol. 1996, 5 (1), 23–28.
• 24. Masihi, K. N.; Madaj, K.; Hintelmann, H.; Gast, G.; Kaneko, Y. Int. J. Immunopharmacol. 1997, 19 (9–10), 463–468.
• 25. Suzuki, M.; Iwashiro, M.; Takatsuki, F.; Kuribayashi, K.; Hamuro, J. Cancer Sci. 1994, 85 (4), 409–417.
• 26. Liu, F.; Ooi, V. E. C.; Fung, M. C. Life Sci. 1999, 64 (12), 1005–1011.
• 27. Jong, S. C.; Birmingham, J. M. Adv. Appl. Microbiol. 1993, 39, 153–184.
• 28. Rincão, V. P.; Yamamoto, K. A.; Ricardo, N. M. P. S.; Soares, S. A.; Meirelles, L. D. P.; Nozawa, C.; Linhares, R. E. C. Virol. J. 2012, 9 (1), 37.
• 29. Turlo, J.; Gutkowska, B.; Herold, F.; Dawidowski, M.; Słowiński, T.; Zobel, A. J. Toxicol. Environ. Heal. Part A 2010, 73 (17–18), 1211–1219.
• 30. Hirasawa, M.; Shouji, N.; Neta, T.; Fukushima, K.; Takada, K. Int. J. Antimicrob. Agents 1999, 11 (2),151–157.

• Document Type: article